C

Cardiff Oncology
D

CRDF

4.74000
USD
0.04
(0.85%)
مغلق
حجم التداول
31,388
الربح لكل سهم
-1
العائد الربحي
-
P/E
-5
حجم السوق
315,324,623
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BLNK
    -0.03500
    (-3.30%)
    1.02500 USD
    H
    HYLN
    -0.11000
    (-5.45%)
    1.91000 USD
    LI
    LI
    1.090
    (4.13%)
    27.470 USD
    N
    NIO
    0.07500
    (1.72%)
    4.44500 USD
    P
    PLUG
    -0.09500
    (-5.43%)
    1.65500 USD
    TSLA
    TSLA
    -16.87
    (-4.76%)
    337.50 USD
    W
    WKHS
    -0.03210
    (-6.20%)
    0.48580 USD
    X
    XPEV
    0.730
    (4.13%)
    18.425 USD
    المزيد
الأخبار
المقالات

العنوان: Cardiff Oncology

القطاع: Healthcare
الصناعة: Biotechnology
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").